Utilization of target-specific, hypersensitive strains of Saccharomyces cerevisiae to determine the mode of action of antifungal compounds.
Target-specific hypersusceptible strains of Saccharomyces cerevisiae were used to screen antifungal compounds. Two novel Erg7p inhibitors were identified, providing proof of principle of the approach taken. However, observed hypersensitivities to antifungals acting via other targets imply that use of this tool to identify the mode of action requires significant deconvolution.
Buurman
Ed T
ET
Department of Microbiology, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA. Ed.Buurman@astrazeneca.com
Andrews
Beth
B
Blodgett
April E
AE
Chavda
Jini S
JS
Schnell
Norbert F
NF
D000935:Antifungal Agents / Q000494:pharmacology*; D007810:Lanosterol / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D008826:Microbial Sensitivity Tests; D011493:Protein Kinase C; D012441:Saccharomyces cerevisiae / Q000187:drug effects* / Q000254:growth & development; D029701:Saccharomyces cerevisiae Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D013261:Sterols / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000935:Antifungal Agents; D029701:Saccharomyces cerevisiae Proteins; D013261:Sterols; D007810:Lanosterol; C015316:lanostenol; C490702:PKC1 protein, S cerevisiae; D011493:Protein Kinase C